If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Concomitant Administration of HPV, Meningococcal, and Tdap Vaccines Shows Favourable Results: Presented at PAS By Jill Stein BALTIMORE, Md -- May 7, 2009 -- Administering the human papillomavirus vaccine (HPV) concurrently with the meningococcal vaccine, and the combined tetanus, diphtheria, and acellular pertussis (Tdap) vaccine in healthy adolescents is usually well tolerated and does not interfere with the immune response of the individual vaccines, researchers stated here at the 2009 Pediatric Academic Societies (PAS) Annual Meeting. "Adolescents and young adults are at high risk for human papillomavirus and other infections, which are preventable by currently available safe and effective, prophylactic vaccines," said Keith Reisinger, MD, Primary Physicians Research, Pittsburgh, Pennsylvania, on May 5. "Concomitant administration would cut the number of visits needed to deliver each vaccine individually, thereby improving compliance and ultimately disease prevention. Dr. Reisinger and colleagues conducted an open-label, multicentre, randomised study of 1,042 patients, aged 10 to 17 years, who were assigned to a concomitant (group A) or nonconcomitant (group B) administration group. Group A received a 0.5 mL dose of the HPV vaccine at day 1, month 2, and month 6 and a 0.5 mL dose of the meningococcal and Tdap vaccines on day 1 at separate injection sites and limbs. Group B received the same dose of the HPV vaccine as group A plus the meningococcal and Tdap vaccine at month 1. Results showed that the immune response following concomitant administration of the 3 vaccines was noninferior to nonconcomitant administration (P < .001 for all HPV vaccine antigens based on geometric mean titres and seroconversion rates). Seroconversion for HPV 6/11/16/18 was >=99% in both concomitant and nonconcomitant vaccination groups. For the meningococcal and Tdap vaccines, concomitant administration was shown to be noninferior to nonconcomitant administration (P < .001 for all antigens). Concomitant administration of the 3 vaccines was usually well tolerated, although the concomitant administration group had higher rates of swelling (HPV vaccine), and bruising and pain (meningococcal and Tdap vaccines). No patient dropped out of the study because of an adverse event. One serious vaccine-related adverse event of transient muscular weakness following the third HPV vaccine injection was reported in group B. Funding for this study was provided by Merck & Co.
[Presentation title: An Open-Label, Randomized, Multicenter Study of Safety, Tolerability, and Immunogenicity of GARDASIL Given Concomitantly with MENACTRA and ADACEL in Healthy Adolescents 11-17 Years of Age. Abstract Number 5529.512]
|
